Published in Nat Rev Cardiol on June 21, 2011
Dichloroacetate (DCA) for the Treatment of Pulmonary Arterial Hypertension | NCT01083524
An endothelial apelin-FGF link mediated by miR-424 and miR-503 is disrupted in pulmonary arterial hypertension. Nat Med (2012) 2.59
Pharmacokinetics and Tolerability of the Novel Oral Prostacyclin IP Receptor Agonist Selexipag. Am J Cardiovasc Drugs (2015) 2.19
MicroRNA-124 controls the proliferative, migratory, and inflammatory phenotype of pulmonary vascular fibroblasts. Circ Res (2013) 1.80
Diminazene attenuates pulmonary hypertension and improves angiogenic progenitor cell functions in experimental models. Am J Respir Crit Care Med (2013) 1.71
Oral delivery of Angiotensin-converting enzyme 2 and Angiotensin-(1-7) bioencapsulated in plant cells attenuates pulmonary hypertension. Hypertension (2014) 1.61
Riociguat for pulmonary arterial hypertension associated with congenital heart disease. Heart (2015) 1.44
Pathobiology of pulmonary arterial hypertension and right ventricular failure. Eur Respir J (2012) 1.39
An international physician survey of pulmonary arterial hypertension management. Pulm Circ (2016) 1.23
Nitric oxide deficiency in pulmonary hypertension: Pathobiology and implications for therapy. Pulm Circ (2013) 1.05
Molecular mechanisms of pulmonary arterial remodeling. Mol Med (2014) 1.05
Blocking macrophage leukotriene b4 prevents endothelial injury and reverses pulmonary hypertension. Sci Transl Med (2013) 1.05
The role of endoplasmic reticulum stress and the unfolded protein response in fibrosis. Curr Opin Rheumatol (2012) 1.03
The soluble guanylate cyclase stimulator riociguat ameliorates pulmonary hypertension induced by hypoxia and SU5416 in rats. PLoS One (2012) 1.00
The microRNA-130/301 family controls vasoconstriction in pulmonary hypertension. J Biol Chem (2014) 0.98
Genetic and hypoxic alterations of the microRNA-210-ISCU1/2 axis promote iron-sulfur deficiency and pulmonary hypertension. EMBO Mol Med (2015) 0.95
Signal transduction in the development of pulmonary arterial hypertension. Pulm Circ (2013) 0.95
Loss of microRNA-17∼92 in smooth muscle cells attenuates experimental pulmonary hypertension via induction of PDZ and LIM domain 5. Am J Respir Crit Care Med (2015) 0.93
An improved method for detecting circulating microRNAs with S-Poly(T) Plus real-time PCR. Sci Rep (2015) 0.92
Interleukin-6/interleukin-21 signaling axis is critical in the pathogenesis of pulmonary arterial hypertension. Proc Natl Acad Sci U S A (2015) 0.90
Vascular remodeling process in pulmonary arterial hypertension, with focus on miR-204 and miR-126 (2013 Grover Conference series). Pulm Circ (2014) 0.90
Protective effects of 10-nitro-oleic acid in a hypoxia-induced murine model of pulmonary hypertension. Am J Respir Cell Mol Biol (2014) 0.88
Hypoxia inducible factor-1 mediates expression of miR-322: potential role in proliferation and migration of pulmonary arterial smooth muscle cells. Sci Rep (2015) 0.87
The zinc transporter ZIP12 regulates the pulmonary vascular response to chronic hypoxia. Nature (2015) 0.86
Fetal production of growth factors and inflammatory mediators predicts pulmonary hypertension in congenital diaphragmatic hernia. Pediatr Res (2013) 0.86
Nano-engineered erythrocyte ghosts as inhalational carriers for delivery of fasudil: preparation and characterization. Pharm Res (2014) 0.86
Translating Research into Improved Patient Care in Pulmonary Arterial Hypertension. Am J Respir Crit Care Med (2016) 0.84
Emerging roles of mitochondria ROS in atherosclerotic lesions: causation or association? J Atheroscler Thromb (2014) 0.84
Endothelial indoleamine 2,3-dioxygenase protects against development of pulmonary hypertension. Am J Respir Crit Care Med (2013) 0.84
A molecular mechanism for therapeutic effects of cGMP-elevating agents in pulmonary arterial hypertension. J Biol Chem (2013) 0.84
Biopterin metabolism and eNOS expression during hypoxic pulmonary hypertension in mice. PLoS One (2013) 0.83
PPARδ agonist GW501516 inhibits PDGF-stimulated pulmonary arterial smooth muscle cell function related to pathological vascular remodeling. Biomed Res Int (2013) 0.83
Extending the translational potential of targeting NO/cGMP-regulated pathways in the CVS. Br J Pharmacol (2015) 0.83
Beneficial effects of a novel agonist of the adenosine A2A receptor on monocrotaline-induced pulmonary hypertension in rats. Br J Pharmacol (2013) 0.83
The peroxisome proliferator-activated receptor β/δ agonist GW0742 has direct protective effects on right heart hypertrophy. Pulm Circ (2013) 0.82
TMEM70: a mutational hot spot in nuclear ATP synthase deficiency with a pivotal role in complex V biogenesis. Neurogenetics (2012) 0.82
Circulating cytokines and growth factors in pediatric pulmonary hypertension. Mediators Inflamm (2012) 0.81
The myriad essential roles of microRNAs in cardiovascular homeostasis and disease. Genes Dis (2014) 0.81
Nonsteroidal antiinflammatory drugs in late pregnancy and persistent pulmonary hypertension of the newborn. Pediatrics (2012) 0.81
Megakaryocytic leukemia 1 (MKL1) ties the epigenetic machinery to hypoxia-induced transactivation of endothelin-1. Nucleic Acids Res (2013) 0.80
Effects of tetrahydrobiopterin oral treatment in hypoxia-induced pulmonary hypertension in rat. Pulm Circ (2014) 0.80
Selective activation of angiotensin AT2 receptors attenuates progression of pulmonary hypertension and inhibits cardiopulmonary fibrosis. Br J Pharmacol (2015) 0.80
Smooth Muscle Insulin-Like Growth Factor-1 Mediates Hypoxia-Induced Pulmonary Hypertension in Neonatal Mice. Am J Respir Cell Mol Biol (2016) 0.79
A report on the use of animal models and phenotyping methods in pulmonary hypertension research. Pulm Circ (2014) 0.79
Endothelial uncoupling protein 2 regulates mitophagy and pulmonary hypertension during intermittent hypoxia. Arterioscler Thromb Vasc Biol (2015) 0.79
Leukotrienes in pulmonary arterial hypertension. Immunol Res (2014) 0.79
C-terminus of ETA/ETB receptors regulate endothelin-1 signal transmission. J Pept Sci (2013) 0.79
Thrombosis, platelets, microparticles and PAH: more than a clot. Drug Discov Today (2014) 0.78
The serotonin transporter promotes a pathological estrogen metabolic pathway in pulmonary hypertension via cytochrome P450 1B1. Pulm Circ (2016) 0.78
PKG-1α leucine zipper domain defect increases pulmonary vascular tone: implications in hypoxic pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol (2014) 0.78
Systematic analysis of blood cell transcriptome in end-stage chronic respiratory diseases. PLoS One (2014) 0.78
MURC deficiency in smooth muscle attenuates pulmonary hypertension. Nat Commun (2016) 0.78
Combination of erythropoietin and sildenafil can effectively attenuate hypoxia-induced pulmonary hypertension in mice. Pulm Circ (2013) 0.77
HIPPO-Integrin-linked Kinase Cross-Talk Controls Self-Sustaining Proliferation and Survival in Pulmonary Hypertension. Am J Respir Crit Care Med (2016) 0.77
To be EndMT or not to be, that is the question in pulmonary hypertension. Protein Cell (2015) 0.77
Population Modeling of Selexipag Pharmacokinetics and Clinical Response Parameters in Patients With Pulmonary Arterial Hypertension. CPT Pharmacometrics Syst Pharmacol (2017) 0.76
Sphingosine-1-phosphate is involved in the occlusive arteriopathy of pulmonary arterial hypertension. Pulm Circ (2016) 0.76
Riociguat for the treatment of pulmonary arterial hypertension associated with connective tissue disease: results from PATENT-1 and PATENT-2. Ann Rheum Dis (2016) 0.76
The pulmonary hypertension academic research consortium. Pulm Circ (2013) 0.76
Chronic obstructive sleep apnea accelerates pulmonary remodeling via TGF-β/miR-185/CoLA1 signaling in a canine model. Oncotarget (2016) 0.76
MiR-328 targeting PIM-1 inhibits proliferation and migration of pulmonary arterial smooth muscle cells in PDGFBB signaling pathway. Oncotarget (2016) 0.76
miR-17/20 Controls Prolyl Hydroxylase 2 (PHD2)/Hypoxia-Inducible Factor 1 (HIF1) to Regulate Pulmonary Artery Smooth Muscle Cell Proliferation. J Am Heart Assoc (2016) 0.76
Therapeutic potential of adipose stem cell-derived conditioned medium against pulmonary hypertension and lung fibrosis. Br J Pharmacol (2016) 0.75
MicroRNA in the Diseased Pulmonary Vasculature: Implications for the Basic Scientist and Clinician. J Korean Soc Hypertens (2013) 0.75
BMPR2 spruces up the endothelium in pulmonary hypertension. Protein Cell (2015) 0.75
Calcium-Sensing Receptor Regulates Cytosolic [Ca (2+) ] and Plays a Major Role in the Development of Pulmonary Hypertension. Front Physiol (2016) 0.75
Efficacy and safety of regenerative cell therapy for pulmonary arterial hypertension in animal models: a preclinical systematic review protocol. Syst Rev (2016) 0.75
Bioavailability, pharmacokinetics, and safety of riociguat given as an oral suspension or crushed tablet with and without food. Pulm Circ (2016) 0.75
Reversal of MicroRNA Dysregulation in an Animal Model of Pulmonary Hypertension. PLoS One (2016) 0.75
D-optimal Design for Preparation and Optimization of Fast Dissolving Bosentan Nanosuspension. Adv Pharm Bull (2016) 0.75
Infections in the immunosuppressed host. Ann Am Thorac Soc (2014) 0.75
The Association between ESR and CRP and Systemic Hypertension in Sarcoidosis. Int J Hypertens (2016) 0.75
Activation of GPER ameliorates experimental pulmonary hypertension in male rats. Eur J Pharm Sci (2016) 0.75
Tipifarnib prevents development of hypoxia-induced pulmonary hypertension. Cardiovasc Res (2017) 0.75
TGF-β1/FGF-2 signaling mediates the 15-HETE-induced differentiation of adventitial fibroblasts into myofibroblasts. Lipids Health Dis (2016) 0.75
Pulmonary vascular remodeling in pulmonary hypertension. Cell Tissue Res (2016) 0.75
Analysis of hypoxia-induced noncoding RNAs reveals metastasis-associated lung adenocarcinoma transcript 1 as an important regulator of vascular smooth muscle cell proliferation. Exp Biol Med (Maywood) (2017) 0.75
Activation of Notch3 promotes pulmonary arterial smooth muscle cells proliferation via Hes1/p27Kip1 signaling pathway. FEBS Open Bio (2015) 0.75
Riociguat for the treatment of pulmonary hypertension: Chinese subgroup analyses and comparison. Heart Asia (2016) 0.75
cAMP-PKA-CaMKII signaling pathway is involved in aggravated cardiotoxicity during Fuzi and Beimu Combination Treatment of Experimental Pulmonary Hypertension. Sci Rep (2016) 0.75
Knockdown of AMPKα2 Promotes Pulmonary Arterial Smooth Muscle Cells Proliferation via mTOR/Skp2/p27(Kip1) Signaling Pathway. Int J Mol Sci (2016) 0.75
Venous thromboembolism: thrombosis, inflammation, and immunothrombosis for clinicians. J Thromb Thrombolysis (2017) 0.75
Nitro-Oleic Acid Prevents Hypoxia- and Asymmetric Dimethylarginine-Induced Pulmonary Endothelial Dysfunction. Cardiovasc Drugs Ther (2016) 0.75
The Role of Transient Receptor Potential Channel 6 Channels in the Pulmonary Vasculature. Front Immunol (2017) 0.75
Mesenchymal stromal cell therapy reduces lung inflammation and vascular remodeling and improves hemodynamics in experimental pulmonary arterial hypertension. Stem Cell Res Ther (2017) 0.75
The safety and pharmacokinetics of rapid iloprost aerosol delivery via the BREELIB nebulizer in pulmonary arterial hypertension. Pulm Circ (2017) 0.75
Effect of gemfibrozil or rifampicin on the pharmacokinetics of selexipag and its active metabolite in healthy subjects. Br J Clin Pharmacol (2017) 0.75
Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med (2005) 9.27
Riociguat for the treatment of pulmonary arterial hypertension. N Engl J Med (2013) 5.60
Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. N Engl J Med (2013) 5.22
Reversal of experimental pulmonary hypertension by PDGF inhibition. J Clin Invest (2005) 4.74
Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial. Lancet (2002) 4.63
Inflammation, growth factors, and pulmonary vascular remodeling. J Am Coll Cardiol (2009) 3.75
Hypoxia-dependent regulation of nonphagocytic NADPH oxidase subunit NOX4 in the pulmonary vasculature. Circ Res (2007) 3.28
Tadalafil therapy for pulmonary arterial hypertension. Circulation (2009) 2.98
Chronic sildenafil treatment inhibits monocrotaline-induced pulmonary hypertension in rats. Am J Respir Crit Care Med (2003) 2.90
Basic science of pulmonary arterial hypertension for clinicians: new concepts and experimental therapies. Circulation (2010) 2.85
Sildenafil increased exercise capacity during hypoxia at low altitudes and at Mount Everest base camp: a randomized, double-blind, placebo-controlled crossover trial. Ann Intern Med (2004) 2.80
Imatinib for the treatment of pulmonary arterial hypertension. N Engl J Med (2005) 2.69
Sildenafil: from angina to erectile dysfunction to pulmonary hypertension and beyond. Nat Rev Drug Discov (2006) 2.64
Imatinib mesylate as add-on therapy for pulmonary arterial hypertension: results of the randomized IMPRES study. Circulation (2013) 2.64
Prevention of bleomycin-induced lung fibrosis by aerosolization of heparin or urokinase in rabbits. Am J Respir Crit Care Med (2003) 2.59
Updated evidence-based treatment algorithm in pulmonary arterial hypertension. J Am Coll Cardiol (2009) 2.57
Histone deacetylation inhibition in pulmonary hypertension: therapeutic potential of valproic acid and suberoylanilide hydroxamic acid. Circulation (2012) 2.54
Inducible NOS inhibition reverses tobacco-smoke-induced emphysema and pulmonary hypertension in mice. Cell (2011) 2.51
Analysis of methylarginine metabolism in the cardiovascular system identifies the lung as a major source of ADMA. Am J Physiol Lung Cell Mol Physiol (2006) 2.29
Simvastatin inhibits inflammatory properties of Staphylococcus aureus alpha-toxin. Circulation (2002) 2.20
Circulating endothelial progenitor cells in patients with Eisenmenger syndrome and idiopathic pulmonary arterial hypertension. Circulation (2008) 2.18
A functional single-nucleotide polymorphism in the TRPC6 gene promoter associated with idiopathic pulmonary arterial hypertension. Circulation (2009) 2.17
Vascular receptor autoantibodies in pulmonary arterial hypertension associated with systemic sclerosis. Am J Respir Crit Care Med (2014) 2.16
Serum levels of vascular endothelial growth factor are elevated in patients with obstructive sleep apnea and severe nighttime hypoxia. Am J Respir Crit Care Med (2002) 2.08
Thrombin impairs alveolar fluid clearance by promoting endocytosis of Na+,K+-ATPase. Am J Respir Cell Mol Biol (2005) 1.91
Pulmonary vascular disease in the developing world. Circulation (2008) 1.90
Classical transient receptor potential channel 6 (TRPC6) is essential for hypoxic pulmonary vasoconstriction and alveolar gas exchange. Proc Natl Acad Sci U S A (2006) 1.89
Two binding sites for [3H]PBR28 in human brain: implications for TSPO PET imaging of neuroinflammation. J Cereb Blood Flow Metab (2010) 1.85
Safety and efficacy of exercise training in various forms of pulmonary hypertension. Eur Respir J (2012) 1.83
Complications of right heart catheterization procedures in patients with pulmonary hypertension in experienced centers. J Am Coll Cardiol (2006) 1.76
Combination therapy with oral sildenafil and inhaled iloprost for severe pulmonary hypertension. Ann Intern Med (2002) 1.72
Bosentan for treatment of inoperable chronic thromboembolic pulmonary hypertension: BENEFiT (Bosentan Effects in iNopErable Forms of chronIc Thromboembolic pulmonary hypertension), a randomized, placebo-controlled trial. J Am Coll Cardiol (2008) 1.69
Imatinib in pulmonary arterial hypertension patients with inadequate response to established therapy. Am J Respir Crit Care Med (2010) 1.69
Omega-3 fatty acids suppress monocyte adhesion to human endothelial cells: role of endothelial PAF generation. Am J Physiol Heart Circ Physiol (2002) 1.67
Oleic acid inhibits alveolar fluid reabsorption: a role in acute respiratory distress syndrome? Am J Respir Crit Care Med (2004) 1.66
Pivotal role for endothelial tetrahydrobiopterin in pulmonary hypertension. Circulation (2005) 1.62
Phosphodiesterase type 5 as a target for the treatment of hypoxia-induced pulmonary hypertension. Circulation (2003) 1.57
Antiproliferative effects of phosphodiesterase type 5 inhibition in human pulmonary artery cells. Am J Respir Crit Care Med (2005) 1.56
Activation of soluble guanylate cyclase reverses experimental pulmonary hypertension and vascular remodeling. Circulation (2006) 1.55
Compartment- and cell-specific expression of coagulation and fibrinolysis factors in the murine lung undergoing inhalational versus intravenous endotoxin application. Thromb Haemost (2004) 1.53
Immunomodulation by n-3- versus n-6-rich lipid emulsions in murine acute lung injury--role of platelet-activating factor receptor. Crit Care Med (2007) 1.52
Increased expression of 5-hydroxytryptamine2A/B receptors in idiopathic pulmonary fibrosis: a rationale for therapeutic intervention. Thorax (2010) 1.52
Iron deficiency and raised hepcidin in idiopathic pulmonary arterial hypertension: clinical prevalence, outcomes, and mechanistic insights. J Am Coll Cardiol (2011) 1.48
Stimulation of soluble guanylate cyclase prevents cigarette smoke-induced pulmonary hypertension and emphysema. Am J Respir Crit Care Med (2014) 1.48
Recent insights into the pathogenesis and therapeutics of pulmonary hypertension. Clin Sci (Lond) (2002) 1.46
Effect of nitric oxide synthase (NOS) inhibition on macro- and microcirculation in a model of rat endotoxic shock. Thromb Haemost (2006) 1.46
Increased levels and reduced catabolism of asymmetric and symmetric dimethylarginines in pulmonary hypertension. FASEB J (2005) 1.44
Oral sildenafil as long-term adjunct therapy to inhaled iloprost in severe pulmonary arterial hypertension. J Am Coll Cardiol (2003) 1.43
Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension: a randomized prospective study. J Am Coll Cardiol (2004) 1.42
Leukotriene-mediated coronary vasoconstriction and loss of myocardial contractility evoked by low doses of Escherichia coli hemolysin in perfused rat hearts. Crit Care Med (2003) 1.41
Comparison of pharmacokinetics and vasodilatory effect of nebulized and infused iloprost in experimental pulmonary hypertension: rapid tolerance development. J Aerosol Med (2006) 1.41
Emerging concepts and translational priorities in pulmonary arterial hypertension. Circulation (2008) 1.39
Inhibition of microRNA-17 improves lung and heart function in experimental pulmonary hypertension. Am J Respir Crit Care Med (2011) 1.37
Cytochrome P450 epoxygenase gene function in hypoxic pulmonary vasoconstriction and pulmonary vascular remodeling. Hypertension (2006) 1.34
Evaluation of angiogenesis using micro-computed tomography in a xenograft mouse model of lung cancer. Neoplasia (2009) 1.34
Upregulation of NAD(P)H oxidase 1 in hypoxia activates hypoxia-inducible factor 1 via increase in reactive oxygen species. Free Radic Biol Med (2004) 1.31
Long-term treatment with sildenafil citrate in pulmonary arterial hypertension: the SUPER-2 study. Chest (2011) 1.29
Bosentan decreases the plasma concentration of sildenafil when coprescribed in pulmonary hypertension. Br J Clin Pharmacol (2005) 1.29
Immune and inflammatory cell involvement in the pathology of idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med (2012) 1.29
Omega-3 vs. omega-6 lipid emulsions exert differential influence on neutrophils in septic shock patients: impact on plasma fatty acids and lipid mediator generation. Intensive Care Med (2003) 1.28
Phosphodiesterase 1 upregulation in pulmonary arterial hypertension: target for reverse-remodeling therapy. Circulation (2007) 1.28
In vivo TRPC functions in the cardiopulmonary vasculature. Cell Calcium (2007) 1.26
Activation of TRPC6 channels is essential for lung ischaemia-reperfusion induced oedema in mice. Nat Commun (2012) 1.25
Long-term ambrisentan therapy for the treatment of pulmonary arterial hypertension. J Am Coll Cardiol (2009) 1.24
Targeting non-malignant disorders with tyrosine kinase inhibitors. Nat Rev Drug Discov (2010) 1.24
Sildenafil for long-term treatment of nonoperable chronic thromboembolic pulmonary hypertension. Am J Respir Crit Care Med (2003) 1.22
Role of hypoxia-inducible factor-1alpha in hypoxia-induced apoptosis of primary alveolar epithelial type II cells. Am J Respir Cell Mol Biol (2005) 1.21
Hypoxic pulmonary artery fibroblasts trigger proliferation of vascular smooth muscle cells: role of hypoxia-inducible transcription factors. FASEB J (2002) 1.20
Mediator generation and signaling events in alveolar epithelial cells attacked by S. aureus alpha-toxin. Am J Physiol Lung Cell Mol Physiol (2002) 1.20
The lectin-like domain of tumor necrosis factor-alpha improves alveolar fluid balance in injured isolated rabbit lungs. Crit Care Med (2008) 1.20
The noncanonical WNT pathway is operative in idiopathic pulmonary arterial hypertension. Am J Respir Cell Mol Biol (2008) 1.19
Impact of mitochondria and NADPH oxidases on acute and sustained hypoxic pulmonary vasoconstriction. Am J Respir Cell Mol Biol (2005) 1.19
Parenteral nutrition with fish oil modulates cytokine response in patients with sepsis. Am J Respir Crit Care Med (2003) 1.19
NOX4 regulates ROS levels under normoxic and hypoxic conditions, triggers proliferation, and inhibits apoptosis in pulmonary artery adventitial fibroblasts. Antioxid Redox Signal (2008) 1.18
Identification of novel Nox4 splice variants with impact on ROS levels in A549 cells. Biochem Biophys Res Commun (2005) 1.18
Molecular genetic characterization of SMAD signaling molecules in pulmonary arterial hypertension. Hum Mutat (2011) 1.18
Proteomic analysis of lung tissues from patients with pulmonary arterial hypertension. Circulation (2010) 1.16
Antiremodeling effects of iloprost and the dual-selective phosphodiesterase 3/4 inhibitor tolafentrine in chronic experimental pulmonary hypertension. Circ Res (2004) 1.16
Simvastatin as a treatment for pulmonary hypertension trial. Am J Respir Crit Care Med (2010) 1.15
Basic features of hypoxic pulmonary vasoconstriction in mice. Respir Physiol Neurobiol (2004) 1.13
Growth differentiation factor-15 in idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med (2008) 1.12
Reduced microRNA-150 is associated with poor survival in pulmonary arterial hypertension. Am J Respir Crit Care Med (2012) 1.11